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Alternative Lengthening of Telomeres (ALT) activity can be deduced from the presence of telomere
length maintenance in the absence of telomerase activity. More convenient assays for ALT utilize
phenotypic markers of ALT activity, but only a few of these assays are potentially deﬁnitive. Here
we assess each of the current ALT assays and their implications for understanding the ALT mecha-
nism. We also review the clinical situations where availability of an ALT activity assay would be
advantageous. The prevalence of ALT ranges from 25% to 60% in sarcomas and 5% to 15% in carcino-
mas. Patients with many of these types of ALT[+] tumors have a poor prognosis.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
All immortalized human cell lines analyzed to date have a telo-
mere length maintenance mechanism (TMM) to compensate for
the telomere shortening that accompanies cellular proliferation
[1]. In many cell lines, the mechanism involves a ribonucleoprotein
enzyme complex, telomerase, that utilizes its integral RNA mole-
cule as a template for reverse transcription of new telomeric
DNA [2]. Other cell lines use a non-telomerase mechanism,
referred to as Alternative Lengthening of Telomeres (ALT) [3].
Although the deﬁnition of ALT encompasses any non-telomerase
TMM [4,5], so far there is no clear evidence that there is more than
one ALT mechanism in human cells. In contrast to RNA-templated
DNA synthesis by telomerase, synthesis of new telomeric DNA by
ALT involves the use of a DNA template [6]. As these TMMs are
either undetectable or have low levels of activity in normal somatic
cells and are relied upon by the vast majority of cancers [7,8], they
provide important targets for detection and treatment of cancer
cells. ALT is being found in an increasing number of cancer types,
including some that have a very poor prognosis with currently
available treatments (as discussed below).
Telomerase-independent telomere length maintenance was
ﬁrst described in yeast, where genetic analyses demonstrated itschemical Societies. Published by E
Road, Westmead, NSW 2145,dependence on homologous recombination (HR) [9]. The existence
of an ALT mechanism in mammalian cells was deduced from the
observation that telomere lengths were maintained for hundreds
of population doublings (PD) in telomerase-negative immortalized
human cell lines [3,10]. Showing that a cell line can maintain the
length of its telomeres in the absence of telomerase for a suitable
number of PD (e.g., 20–30) is still the only deﬁnitive test for ALT
activity, but in a number of regards it is an unsatisfactory assay.
First, it is not suitable for detecting ALT activity in human tumors,
where it is usually not practicable or ethical to obtain serial sam-
ples. Second, the need to demonstrate that the cells or tumors
are telomerase-negative means that this assay is not suitable for
detecting ALT in situations where both ALT and telomerase may
be present. Although there are no known examples of ALT and tel-
omerase being activated spontaneously in the same cells, it has
been shown experimentally that both mechanisms can co-exist
in cells [11–14]. Third, it takes a long time – 20 PD may take more
than a month – and, fourth, this test can only determine whether
ALT activity is present and is unable to measure the amount of
activity; both of these aspects make it very unsuitable as an assay
to screen large numbers of chemical compounds to ﬁnd ALT inhib-
itors, and thereby ﬁnd anticancer treatments that target this mech-
anism. Finally, the need to demonstrate that telomere length is
maintained excludes the possibility of detecting ALT activity levels
that are insufﬁcient to completely prevent telomere shortening.
The ability to do this will be essential for understanding the role
of ALT in normal biology and the potential side-effects of anti-
ALT treatments.lsevier B.V. All rights reserved.
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widely used being the TRAP assay [15]), which was originally
detected by its enzymatic activity [16]. This means that it can be
detected in tumor samples and cell lines regardless of whether
ALT is also present. It can also be detected in some types of normal
cells, where the level of telomerase activity is insufﬁcient to com-
pletely prevent telomere shortening. Telomerase activity assays
are also rapid and can be quantitative. Ideally, assays for ALT activ-
ity would be able to provide the same type of information. Telome-
rase activity assays, however, simply indicate the presence and
amount of active enzyme and yield no information about its activity
at telomeres [17]. The activity of telomerase in vivo appears to be
regulated by the accessibility of telomere termini and by cis-acting
telomeric factors [18]. In this important regard, analyses of telome-
rase activity are currently no more advanced than analyses of ALT,
because the only way of assessing telomerase activity at human
telomeres in vivo is to do medium- to long-term studies of cultured
cells to analyze telomere lengths for a suitable number of PD.
Without the availability of an ALT activity assay, the presence of
ALT in tumors has been inferred from phenotypic features that are
characteristic of ALT[+] cell lines. There is a growing list of thesephe-
notypic characteristics, but inmost cases thenatureof their relation-
ship to ALT activity is unclear, which means that their use as a
surrogate for ALT activity when telomere-related factors are per-
turbed experimentally is fraught with difﬁculties of interpretation.
However, a few ALT markers may directly assay an aspect of the
ALT mechanism or could be based on an intermediary molecule,
and hence might be able to be used as a deﬁnitive assay for ALT.
Here we review these phenotypic characteristics of ALT-positive
cell lines and tumors, the extent to which they can be relied on for
detecting the presence of ALT activity, and progress towards an ALT
activity assay. We also brieﬂy reﬂect upon the implications these
ALT characteristics have for understanding the mechanism of
ALT, models of which have been presented in a recent review
[19]. Finally, we summarize the increasing number of cancer types
in which ALT activity has been detected, and clinical situations
where availability of an ALT activity assay would be advantageous.2. ALT assays
2.1. The ‘‘gold standard”: maintenance of telomeres in the absence of
telomerase activity
The only test for ALT that can be regarded as deﬁnitive at pres-
ent is to determine whether telomere length is maintained in the
absence of telomerase activity [3], although as a practical assay
this has the drawbacks listed above. It can only be used for cell
lines (or animal model systems) where telomerase is absent, and
it is a medium- to long-term assay that is essentially non-quantita-
tive. Even in clonally derived cell lines, there can be minor ﬂuctu-
ations in telomere length from passage to passage, so in practice it
is necessary to culture cells for at least 20–30 PD in order to be
conﬁdent that telomere length is being maintained, and ideally
the absence of telomerase activity should be demonstrated at mul-
tiple PD levels. Because maintenance of telomere length in the ab-
sence of telomerase has never been demonstrated in non-
immortalized human cells, a useful conﬁrmatory test is to demon-
strate that the cells being studied are in fact immortalized. This is
usually done by determining whether the cells are able to grow in
culture for >100 PD.
Limited quantitative information can be extracted from this as-
say in a carefully controlled context. In an ALT[+] cell line, inhibi-
tion of ALT can be detected by demonstrating that telomeres
shorten steadily with increasing PD [20–22]. For example, in an
ALT[+] ﬁbroblast cell line in which the MRE11/RAD50/NBS1(MRN) complex was sequestered following expression of high lev-
els of SP100 protein, telomere length declined linearly (over sev-
eral time-points) at a rate of approximately 120 base pairs (bp)/
PD. This is within the range of telomere attrition rates in normal
human ﬁbroblasts that do not have any detectable telomere main-
tenance mechanism, and is consistent with ALT having been
almost completely inhibited in these cells [20]. The rate of
telomere attrition following treatment with a candidate ALT
inhibitor can yield quantitative information about the extent of
inhibition. However, the length of time required for this assay re-
sults in the possibility of mutations or other adaptations occurring
in the cultured cells that confound the results. Moreover, it may
not be possible to use this assay to demonstrate that a candidate
has ALT inhibitor activity if it also has effects that result in cell
death or senescence within that time period, which may explain
the difﬁculty demonstrating telomere shortening in some circum-
stances [23–25]. A more practical assay is clearly required.
2.2. Telomere length heterogeneity
One of the ﬁrst hallmarks found in immortalized human cell
lines that use the ALT TMM was a characteristic pattern of telo-
mere lengths (as analyzed by terminal restriction fragment [TRF]
Southern blots), ranging from very short to extremely long, and
with a modal length approximately twice that in comparable telo-
merase[+] or normal cells [3,26]. The telomere length heterogene-
ity can also be visualized in metaphase spreads by telomere
ﬂuorescence in situ hybridization (FISH) [14]. Telomere lengths
in ALT cells are not normally distributed, in contrast to telome-
rase[+] cells, most of which regulate their telomere lengths about
a mean of 5–10 kb [27,28]. Analyses of single telomeres in ALT[+]
cells revealed sporadic, unsynchronized increases and decreases
in telomere lengths of a variable amount (that are sometimes very
large – up to 20 kb) on a background of gradual erosion (50 bp/
PD) [29], which appear to be responsible for the broad distribution
of ALT telomere lengths [28]. This pattern is established within one
PD (equivalent to approximately 17 cell generations, which are re-
quired for one clone to overgrow a culture that is in crisis) of ALT
being activated during immortalization in vitro [30].
The long heterogeneous telomere length pattern remains the
best-established marker for ALT in human cells, including tumors
archived under conditions where it is possible to extract high-qual-
ity genomic DNA [5,31]. In tumor specimens the distinction be-
tween ALT[+] and ALT[] is sometimes less obvious due to tumor
heterogeneity and non-tumor cells in the specimen [31]. Tumor
length heterogeneity needs to be interpreted cautiously, especially
under experimentally perturbed conditions, as this characteristic
may not be completely ALT-speciﬁc. Long and/or heterogeneous
telomeres are seen in telomerase[+] cell lines when expression of
hTR or hTERT at supra-physiological levels challenges the telomere
length regulatory mechanism with excessive telomere lengthening
[32,33]. Conversely, it may not be necessary for cells using the ALT
mechanism to have long telomeres [34].
2.3. Telomere length ﬂuctuation
Because rapid, unsynchronized changes in telomere length
cause telomere length heterogeneity [29], detection of these length
changes may be regarded as closely related to detection of length
heterogeneity. However, detection of ongoing ﬂuctuations in indi-
vidual telomere lengths may be useful in the situation where
length heterogeneity has already been established by ALT activity,
and it is necessary to determine whether an experimental manip-
ulation has subsequently repressed ALT [14]. This could potentially
be done by subcloning followed by Southern blot analysis of indi-
vidual telomere lengths using a probe for a DNA marker inserted in
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ing an ALT[+] cell line with a candidate ALT repressor, subcloning,
preparing metaphase spreads, and then determining the extent of
telomere length ﬂuctuation by measuring the variation in the ratio
of p:q-arm telomere FISH signal intensity on an easily identiﬁable
individual chromosome (e.g., the Y chromosome, or a marker chro-
mosome, if present as a single copy), every example of which with-
in the cell population is the progeny of a single chromosome
[14,20]. If the unsynchronized changes in length generated by
ALT activity have been eliminated by the treatment, then every
example of this chromosome will have the same p:q ratio, even
though the telomere lengths within the cell may remain highly
heterogeneous because of previous ALT activity. If the treatment
has had no effect on ALT activity, then the variability of the p:q ra-
tio will be similar to the variability on the same chromosome in
subclones of untreated cells. The utility of this technique is limited
by the need to obtain metaphase spreads, and the sources of inac-
curacy in quantitation of telomere lengths in a relatively small
number of cells by FISH, the consequences of which become more
problematic when telomeres are short. If an individual chromo-
some is not readily identiﬁable by karyotypic analysis, it may be
possible to measure telomere length ﬂuctuations using single telo-
mere length analysis (STELA) [28]. It needs to be kept in mind that
ﬂuctuations in telomere length may not be speciﬁc for ALT because
they potentially may also be caused by unsynchronized telomeric
deletions in the absence of length maintenance.
2.4. ALT-associated PML bodies (APBs)
Like telomere length heterogeneity, the APB assay [30] is a well-
established test for ALT, and has been especially useful for deter-
mining the ALT status of tumors as it can be used on parafﬁn-
embedded specimens, and it is not affected by intra-tumoral heter-
ogeneity in TMM because it assesses individual cells [31]. APBs are
subsets of the ubiquitous PML nuclear bodies, which are foci of
PML protein that bring many other nuclear proteins close together
at one location [35]. PML bodies contribute to many diverse nucle-
ar processes, including DNA repair and replication. PML bodies can
function as active sites for nuclear processes requiring macromo-
lecular interactions, as storage depots, or as sites involved in deg-
radation of macromolecules [36]. These bodies can be statically
bound to the nuclear matrix or mobile, large or small, and com-
posed of several different isoforms of PML [37–39]. The subset of
PML bodies that contain telomeric chromatin and DNA homol-
ogy-directed repair and replication proteins are indicative of an ac-
tive ALT mechanism [23,30,40–43] and PML bodies containing
telomeric chromatin are deﬁned as APBs [30]. Localization of telo-
meres to PML bodies requires the presence of the PML isoform,
PML3 [44], the SUMOylation of telomeric chromatin by the
SMC5/6 complex [21] and a functional MRN complex [40,45]. The
MRN complex is involved in most aspects of DNA repair including
HR [46].
Frequently occurring APB[+] nuclei have only been documented
in ALT[+] cell lines and tumors [30,47,48]. APBs with telomeric sig-
nal intensities greater than those arising at the telomeres usually
occur in around 10% of nuclei in an exponentially growing ALT[+]
cell line [30], but smaller colocalizations of PML and telomeric
DNA can be seen in most if not all ALT[+] nuclei under optimal con-
ditions (A. Muntoni, H. Pickett, R. Reddel, unpublished results). The
APBs with telomeric signals greater than those of the telomeres
could arise from aggregations of telomeres [49–51] in the PML
bodies and/or extrachromosomal telomeric repeats [52]. These
large APBs usually increase in frequency with any cellular stress
that causes cell cycle arrest, including senescence [43,45,52].
APBs could be an exaggeration of a transient event in G2 when
PML bodies are proposed to be the sites for resolution and conden-sation of newly replicated tandem repeat DNA. Regarding juxta-
centromeric satellite DNA, there is some evidence that BLM and
TopIIIa in PML bodies may help resolve inappropriate recombina-
tion products formed during replication of repetitive DNA, and
then BRCA1 and HP1 proteins (as well as ATRX and DAXX) in the
same PML bodies may help condensation and reestablishment of
the heterochromatin state [53]. Although this process is normally
only transient, in the immunodeﬁciency, centromeric instability
and facial dysmorphy (ICF) syndrome, defective DNA methylation
of the juxtacentromeric repetitive DNA causes much larger and
longer colocalizations of the DNA and repair proteins inside the
PML bodies. In ALT[+] cells, BLM and TopIIIa are present in APBs
and are required for cell viability [24,54], possibly by preventing
unresolved, post-replicative, recombination intermediates [24].
BRCA1 and HP1 proteins are also present in APBs [40,43] and
HP1a and HP1c are required for formation of large APBs [43]. APBs
can rarely be seen in non-ALT cells (A. Muntoni and R. Reddel,
unpublished results), so it would be interesting to determine if this
is related to early G2. Moreover, analogous to the effects of defec-
tive pericentromeric methylation in ICF syndrome, defective subt-
elomeric methylation induces APBs (long-lasting telomeric DNA in
PML nuclear bodies) in mouse cells [55]. Although not ubiquitous,
subtelomeric hypomethylation does occur on some chromosomes
of human ALT cells, so it seems possible that this may contribute
to APB formation [56,57].
A question regarding APBs that remains unanswered is whether
their association with ALT is due to the abnormal telomeres in ALT
cells and/or to a direct involvement in the ALT mechanism. If the
telomeric DNA inside APBs does contain inappropriate replication
or recombination structures, these could facilitate telomere repeat
ampliﬁcation by HR-primed replication in ALT cells before being
resolved. APBs are sites of active DNA synthesis [41,47], although
this DNA synthesis may be limited to the repair of aberrant repli-
cation or recombination structures at ALT telomeres. There is
strong circumstantial evidence that ALT activity can occur in APBs.
The MRN and SMC5/6 complexes, which are needed for the ALT
mechanism, are present in APBs [20,21]. Furthermore, APBs disap-
pear or decrease when ALT is inhibited by sequestration or knock-
down of these complexes [20–22,45] and APBs are seen soon after
activation of ALT [30]. PML bodies often seem to be redundant for
their many functions [58], so even if APBs are sites of ALT activity it
would not be surprising if they are not essential for ALT. There are
two unusual ALT cell lines that do not have APBs (29/31 ALT[+] cell
lines tested have APBs; Refs. [30,48] and J. Henson and R. Reddel,
unpublished results). One of these, AG11395, still has aggregates
of telomeric DNA and HR proteins – but without PML protein
[59,60]. The second ALT cell line without APBs also lacks long het-
erogeneous telomeres and t-circles (a type of telomeric circular
DNA associated with ALT, described below) [34]. This could indi-
cate an association between these three ALT markers, which is also
supported by the observation that telomerase-positive cell lines
which had excessively elongated telomeres from telomerase over-
expression were found to have t-circles and a low frequency of
APBs [33]. Occasional APBs could be a marker of long telomeres
and increased trimming rather than a direct marker of the ALT
mechanism.
A modiﬁcation has been made to the APB assay to use it as a test
for inhibition of APB formation and, potentially, inhibitors of the
ALT mechanism. Reduction of methionine in the growth medium
for the IIICF/c ALT cell line increases the percentage of cells con-
taining large APBs from 5% to >50% [45]. This makes measuring
changes in APB levels a more sensitive test for changes in ALT
activity and a more rapid test for inhibition of ALT, because even
if APBs persist for a while after inhibition of ALT [61], an induction
in the number of APBs should only be seen if ALT activity is still
present. This test may not be directly related to ALT activity, so sec-
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inhibiting APB formation also inhibit ALT activity. Although rea-
sonably rapid, this test is dependent on the cells remaining viable
for three to four days after treatment. Methionine restriction has
been useful in identifying proteins required for APB formation
and demonstrating that APBs can be induced in G0/G1-arrested
ALT[+] cells [45], in contrast to the usual association of APBs with
G2-arrested ALT[+] cells [47,48,59]. The induction of APBs by
methionine restriction is likely to result from the activation of
the signaling pathways that lead to cell cycle arrest [43]. It has
been suggested that methionine depletion might also lead to a
methylation defect in the telomeric chromatin [45], which may
also inﬂuence APB formation.
2.5. Copying of telomeric tags from one telomere to another
ALT ampliﬁcation of speciﬁcally designed telomeric tags has
been used to show that a telomere can template the ALT-mediated
extension of either itself [62] or another telomere [6]. Because
ampliﬁcation of these tags indicates the synthesis of new telomeric
DNA from a DNA template, testing for telomere tag ampliﬁcation is
a speciﬁc test for ALT. The tag designed to demonstrate inter-telo-
meric copying has been used to conﬁrm ALT status [33,59]. These
techniques are time-consuming to set up as they involve genera-Fig. 1. Mechanisms for ALT telomere elongation. The ALT mechanism involves both int
telomeres (as illustrated) have been used to demonstrate inter-allelic ampliﬁcation [6] an
[62]. This mechanism most likely involves HR-primed replication. However, extrachromo
by recombination of the ampliﬁed DNA with a telomere could also be involved.tion of clones with telomerically integrated DNA tags. Since the
two different tags separately test for inter-allelic or intra-allelic
copying (Fig. 1), it is possible that ALT activity could be missed if
the ALT mechanism can operate either without any inter-allelic
or without any intra-allelic copying, or without both by using un-
tagged extrachromosomal telomeric DNA as the copy template.
2.6. Telomeric t-circles
An increase in the level of t-circles has been used as a marker
for ALT activity [25,34,59,63–65], however t-circles do not appear
to be essential for, or conﬁned to the ALT mechanism. Of the vari-
ety of types of circular telomeric DNA in ALT cells, t-circles refer to
double stranded (ds)DNA telomeric circles that are relaxed (not
supercoiled) due to nicks in both strands [64,66] (Fig. 2). These cir-
cles are thought to be formed when the branch point of the telo-
meric t-loop migrates, forming a Holliday junction that is then
resolved with XRCC3 [64]. One reason for a general increase in t-
circles in ALT cells could be as a by-product of trimming long telo-
meres [33]. The only ALT cell line without long telomeres is also
the only known ALT cell line with low levels of t-circles [34]. T-cir-
cles can be formed independently of ALT in response to DNA dam-
age [67,68]. They may also be generated following depletion of Ku
[65,69] or over-expression of mutant TRF2 lacking its basic domainra- and inter-allelic ampliﬁcation of telomeric DNA. DNA tags inserted into single
d speciﬁcally designed tags have been used to distinguish intra-allelic ampliﬁcation
somal ampliﬁcation of telomeric DNA by rolling circle ampliﬁcation (RCA), followed
Fig. 2. Telomeric circles. Telomeric t-circles have nicks in both strands [64] and are
unable to sustain RCA reactions [66]. Telomeric C-circles and G-circles are deﬁned
by their ability to self-prime RCA of telomeric C-strand and G-strand templates,
respectively. While this deﬁnition of C-circles could include a variety of different
structures, it requires that C-circles must have at least one 30end available on an
uninterrupted template C-strand. Similarly, different possible structures for G-
circles are shown.
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propriate HR [70,71]. Furthermore, t-circles may form following
depletion of either ORC2 [68] or WRN [72], possibly because these
proteins are required to avoid replication difﬁculties in the leading
[73] or the lagging [74] strand, respectively. The long telomeres in
ALT cells may be especially dependent on these proteins. Further
evidence that increased t-circles may not be directly related to
the ALT mechanism comes from the observation that although
both ALT and t-circles depend on NBS1 [22,64], t-circle formation
appears to be more sensitive than the ALT mechanism to decreased
NBS1 levels [75].
2.7. Minisatellite instability
Tandem repeat instability at telomeres and the MS32 minisatel-
lite has been used to investigate ALT activity [28,76]. Telomere var-
iant repeat mapping of the proximal telomere (where variant
repeats are common) indicates that intra- and inter-allelic recom-
bination are increased in ALT telomeres [28,77], although HR is not
generally elevated in ALT[+] cells [78]. Telomeric tandem repeats
are a type of minisatellite tandem repeat, and ALT[+] cells have in-
creased tandem repeat instability at the MS32 minisatellite locus
[76] and at minisatellites detected by the 33.15 and 33.6 multi-lo-
cus probes [79], but not at ﬁve other minisatellite loci [76]. Mini-
satellites are tandem repeats of 6–100 bp units that for technical
reasons were traditionally deﬁned to have array lengths of
>500 bp [80]. The increased tandem repeat variability associated
with ALT was not found in microsatellites, which usually have
shorter repeat units and a shorter array length than minisatellite
repeats [76]. The frequency of MS32 mutation varied among 15ALT[+] cell lines, but was on average 55-fold greater than in ALT[]
cell lines. The changes in ALT were different to both the simple
deletions seen in normal somatic cells and the typical germ-line in-
ter-allelic recombinations that are clustered near a meiotic
cross-over hotspot, and included complex internal changes in the
sequence of variant repeat units, suggestive of multiple events
[76]. The tandem repeats known to have length instability in ALT
have G and C segregated into one G-rich and one C-rich strand.
Although G:C strand segregation is common to most minisatellite
repeats, such as the MS1 minisatellite that is not unstable in ALT
cells [76], it may contribute to the instability because it can cause
mispairing, formation of intrahelical pseudoknots and interhelical
associations in vitro [81]. This could promote HR and interfere with
DNA replication. G:C segregation-facilitated instability could be re-
lated to increased ALT activation in WRN null mouse cells [82] and
possibly cancers and cell lines from WRN patients (Refs. [59,60]
and J. Henson and R, Reddel, unpublished results). WRN helicase
is presumably involved in unwinding G-quartets that can form in
the G-strand telomeric template for lagging strand DNA synthesis,
potentially causing large excisions of the lagging strand replicated
telomere [74]. Because general tandem repeat length plasticity is
thought to be caused via tandem repeat excision of circular inter-
mediates and reintegration of their rolling circle ampliﬁcation
(RCA) products [83], it will be interesting to determine whether
there are DNA circles of these unstable tandem repeats in ALT cells.
2.8. Telomere-sister chromatid exchange (T-SCE)
T-SCE is increased in ALT cells [84,85] and has been used as an
assay for ALT [25,86,87], although it may not be an ALT marker that
can be depended on in isolation to reﬂect ALT activity. T-SCE can be
detected by Chromosome Orientation (CO)-FISH [88], which in-
volves complete destruction of the newly synthesized DNA strand,
leaving the template strand intact for FISH with telomere strand-
speciﬁc probes that can indicate if a cross-over event occurred after
replication between a leading and lagging strand telomere [84]. If
probes for both C-rich (leading strand template) and G-rich (lag-
ging strand template) sequences are used, then it can be conﬁrmed
that the cross-over event involved the sister chromatid (i.e., was a
T-SCE). T-SCE reﬂects increased recombination at the telomere
rather than ALT activity per se, although this characteristic does
appear to be tightly linked to ALT activity. A marked increase in
T-SCEs is generally only seen in ALT[+] cells [84,85], although a re-
cent report identiﬁed four telomerase[+] cell lines with T-SCE lev-
els similar to those found in ALT[+] cells [89]. The value of T-SCE as
a marker for ALT was demonstrated in an ALT[+] clone that lost
other ALT markers (long heterogeneous telomere lengths, APBs
and t-circles) but retained elevated T-SCEs [34]. This suggests that
T-SCE may be more tightly linked to the ALT mechanism than most
other markers. On the other hand, an ALT[+] cell line depleted for
MUS81 had reduced T-SCE without any signiﬁcant reduction in
telomere length maintenance over 2 weeks (although limited ALT
cell viability resulting from MUS81 depletion may not have
allowed sufﬁcient time to observe telomere shortening) [25]. In
mouse cells, a small increase in T-SCEs was seen following DNA
damage [90] or severe telomere shortening [91]. In general, short
telomeres are thought to be more recombinogenic because they
are more mobile [51], have a more open chromatin structure
[92], and elicit a DNA damage response (DDR) [49]. Thus the in-
creased T-SCE seen in ALT may partly reﬂect the high proportion
of critically short telomeres that are a feature of ALT cells [30],
rather than being directly related to the ALT mechanism. Up to
30% of chromosome ends in ALT cells have been reported as having
undetectable telomeres [51] and even some easily detectable ALT
telomeres may be ‘‘functionally short” due to an increased number
of variant telomeric repeats [28,66,77,93].
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plate for the ALT mechanism. If ALT-mediated elongation of a telo-
mere occurs after priming replication by recombination with the
sister chromatid telomere, and if the resultant structure is resolved
by a cross-over event, then this would result in a T-SCE. The newly
elongated section of the telomere would not be visible, however, as
both of its strands would be destroyed in the CO-FISH technique.
Sister chromatid-primed elongation is consistent with the observa-
tion that intra-allelic tag ampliﬁcation occurs in ALT cells [62],
although rolling t-loop replication is another possible explanation
of this observation (Fig. 1). Telomere CO-FISH may not detect roll-
ing t-loop elongation, elongation primed by inter-telomeric recom-
bination, or telomere elongation by integration of telomeric
repeats from RCA.
It has been suggested that ALT could occur without ampliﬁca-
tion of telomeric DNA, by a mechanism involving unequal T-SCE
and selective segregation of all sister chromatids with the longer
telomeres (on both the p and q arms, presumably) into the same
daughter cell, leaving the other sacriﬁcial daughter cell with
mostly short telomeres [94]. However, there is no evidence for un-
equal T-SCE (resulting in one short and one long telomere) being
common in ALT, or for selective segregation of the chromatids with
longer telomeres into one of the daughter cells. Furthermore,
ampliﬁcation of telomeric DNA is known to occur in ALT [6,62],
and commonly from inter-telomeric sources [6,28,77]. Thus un-
equal T-SCE does not appear to be a likely ALT mechanism
although unequal inter-telomeric exchanges could slow down
the onset of cellular senescence in mortal cells [95,96].
2.9. Single stranded C-strand telomeric DNA (ss-C-strand)
Ss-C-strand is detectable in ALT[+] cells but not in telomerase[+]
or mortal cells [97,98], and is a marker for ALT. Single stranded G-
strand telomeric DNA (ss-G-strand) occurs in all cells (normal and
immortal) and is bound by POT1 to prevent an RPA/ATR DDR and
recombination [99]. The apparent lack of a corresponding ss-C-
strand binding protein to prevent ALT-associated ss-C-strand elic-
iting a DDR and initiating recombination motivated our original
interest in looking for ss-C-strand in ALT cells [97]. If some ss-C-
strand exists as telomeric interstitial gaps, then this could explain
in part why there is an increased DDR at ALT telomeres without in-
creased telomeric fusions [49]. Most of the ss-C-strand in ALT is
likely to be in extrachromosomal circular DNA [100] and ss-C-
strand can also be found in APBs [97,98]. The precise relationship
between ss-C-strand and the ALT mechanism needs to be further
investigated, but its detection by PCR could potentially be used
as a sensitive assay for ALT.
2.10. C-circles: self-priming circular telomeric C-strand templates
C-circles, deﬁned as self-priming circular telomeric C-strand
templates for RCA [66] have been shown to be a speciﬁc and useful
assay for ALT activity. This is possibly the most convenient and ver-
satile of the ALT assays, but nevertheless needs to be interpreted
with caution until it can be determined whether C-circles are an
integral part of the ALT mechanism or just another associated char-
acteristic. Our deﬁnition of C-circles and G-circles, respectively, as
self-priming telomeric C-strand and G-strand templates for RCA
distinguishes them from t-circles that have nicks or gaps in both
strands [64] and are therefore unable to sustain RCA [66]. While
this deﬁnition of C-circles could include a variety of different struc-
tures, the self-priming component of the deﬁnition requires that C-
circles must have at least one 30end available on an uninterrupted
C-strand template (Fig. 2).
Both C- and G-circles are speciﬁc to ALT, but C-circles appear
more numerous in ALT cells and have been more extensively inves-tigated [66]. C-circle levels in non-ALT cells are below background
levels of the standard C-circle assay [66] and normal human ﬁbro-
blasts have levels 1000-fold less than the average ALT[+] cell (J.
Henson and R. Reddel, unpublished results). All 19 ALT[+] cell lines
tested had raised levels of C-circles, including ALT[+] cell lines lack-
ing t-circles and the established ALT markers of long heteroge-
neous telomeres and APBs [66]. C-circles were not detected in
any mortal or telomerase[+] cell line, even in one induced to have
long heterogeneous telomeres, t-circles and APBs. C-circles ap-
peared when ALT was activated and decayed rapidly after inhibi-
tion of ALT. Given the speciﬁcity of C-circles for ALT and their
short half life, it is likely that they are an integral part of the ALT
mechanism. The simplest explanation may be that C-circles are
ALT RCA intermediates, which is supported by the observation that
depletion of the RPA protein (which binds ssDNA) led to an ALT-
speciﬁc, dramatic increase of ss-G-strand [98].
The C-circle is the ﬁrst candidate for an ALT speciﬁc molecule
and an eligible target for a simple and versatile ALT assay. Since
C-circles are self-priming RCA templates, they are an ideal sub-
strate for detection by an isothermic polymerase (RCA) reaction
that could readily be adapted for use by standard clinical pathology
laboratories. The presence of C-circles in the blood of ALT[+] cancer
patients means that the C-circle (CC) Assay could be used as rou-
tine clinical test for ALT activity [66]. The CC Assay was proven
to be a sensitive and speciﬁc test for ALT. It was able to detect as
few as 100 ALT[+] cells and clearly distinguished ALT[+] from
ALT[] cells. The fact that it was quantitative and responded with-
in 24 h to inhibition of ALT means it is the ﬁrst ALT assay that could
be used to screen for ALT inhibitors. If C-circles can be explicitly
demonstrated to be a required intermediate of the ALT mechanism,
then the CC Assay could provide a deﬁnitive and practical ALT as-
say that could be used, for example, to determine the exact rela-
tionship to the ALT mechanism of important DNA repair proteins
such as MUS81 [25], BLM [54], mono-ubiquinated FANCD2 [87],
TopIIIa [24], Rad51D [23] and FEN1 [101]. It has been difﬁcult to
be certain whether these proteins are required for ALT telomere
elongation or for prevention and/or processing of aberrant replica-
tion and recombination structures in ALT telomeres. It is possible
that ALT may encompass a variety of related mechanisms and
the CC Assay might test for only one of these. The C-circle levels
were elevated in all 19 ALT[+] cell lines tested that were from a
wide range of origins, although they did vary over a 200-fold range.
Thus it is theoretically possible that C-circles reﬂect a form of the
ALT mechanism that is ubiquitous but can vary in importance in
different ALT cells.3. Choosing an ALT assay
Detection of ALT often requires choosing the most appropriate
ALT assays for the experimental context (Table 1). On the balance
of the current evidence, the best frontline tests still include the
established ALT markers of long heterogeneous telomere lengths
and the presence of APBs. Assays for these characteristics of ALT
are relatively convenient, reliable and have been extensively
tested. The CC Assay and (if metaphase spreads are obtainable)
the T-SCE assay are also convenient, although the latter is not al-
ways a reliable indicator of ALT activity. The CC Assay has the
added advantage of being quantitative. The only established deﬁn-
itive test for ALT is telomere length maintenance in the absence of
telomerase activity, although this is not always practical. Using
telomeric tags to detect intra- or inter-molecular telomere ampli-
ﬁcation directly tests for the ALT mechanism and could also be
used as a deﬁnitive ALT assay. However, this should be interpreted
with caution as it is theoretically possible that it may not test all
aspects of the ALT mechanism – especially if only inter-molecular
Table 1
ALT assays.




30 PD N/A None known ALT coexisting with telomerase
Telomere length
distribution
1  106 cells (TRF
analysis; <1000 cells
with STELA)
Frozen specimens hTR and hTERT overexpression
[32,33]




1  103 cells Frozen and parafﬁn
embedded specimens
hTR overexpression [33]; hTERT
overexpression [97]
ALT[+] cell line AG11395 [59]; ALT[+]
subclone with catalytically dead
hTERT [34]
Telomere length ﬂuctuation Clonal population,
marker chromosome
N/A Not extensively tested Not extensively tested
T-circles (2D gel) 1  107 cells Not tested Hep 3B hepatoma ALT[] cell line
(Ref. [67], A. Englezou unpub.
results). DNA Damage [67,68]. hTR
overexpression [33]. Depletion or
disruption of TRF2 [64], Ku [65,69]
WRN [72], ORC2 [68]
ALT[+] subclone with catalytically






N/A Not extensively tested Not extensively tested
Telomeric repeat instability <1  103 cells Frozen specimens May detect pre-ALT or non-ALT




<1  103 cells Frozen specimens May detect pre-ALT or non-ALT
recombination in tumors [28]
Five of eight ALT[+] sarcomas




Mitotic cells N/A Four telomerase[+] cell lines [120];
Cells with short [91] or damaged [90]
telomeres
Possibly MUS81 depletion [25]
C-circle assay 1  103 cells Frozen specimens None known None known
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ic length ﬂuctuations could be considered another ALT mecha-
nism-directed assay, but may not be speciﬁc as telomeric
deletions in the absence of length maintenance could theoretically
cause increased telomeric length ﬂuctuations. The demonstrated
speciﬁcity of the CC Assay for ALT activity indicates its potential
to be used as a deﬁnitive assay. However, this needs to be directly
proven by showing that C-circles are an intermediate molecule in
the ALT mechanism. Even then caution would be required as the
CC Assay may only test for RCA and may miss intra- or inter-telo-
meric ampliﬁcation. All of the ALT assays described (Table 1) could
be used to give a better understanding of the ALT status of the sys-
tem being investigated and, in situations where the more deﬁnitive
assays are impractical, it may be necessary to perform several
assays.
4. Detection of ALT in human tumors
Partly due to lack of an assay for ALT that is practical for screen-
ing large numbers of tumors, the prevalence of ALT is not known
for many tumor types, including the most common cancers. So
far, a number of areas in oncology have been identiﬁed which
would beneﬁt from being able to quantitate or inhibit ALT activity
(Table 2). ALT is the TMM for approximately 50% of osteosarcomas,
30% of soft tissue sarcomas, 25% of the primary brain tumor, glio-
blastoma multiforme (GBM), and 10% of neuroblastomas, with the
median survival for patients with these ALT[+] cancers ranging
from 2 to 5 years (Table 2). Although ALT[+] tumors appear to be
less likely to metastasize [31,102], the presence of ALT usually
associates with same or worse survival compared to ALT[] coun-
terparts (Table 2). For example, in liposarcomas the presence of
ALT was found to confer a worse prognosis than telomerase activ-
ity [103]. The exception is GBM where the presence of ALT con-
ferred a 2–3-fold longer survival [31,104]. ALT was found to be
the best prognostic indicator in GBM, for which the median sur-
vival is less than 1 year [104]. Detection of ALT in GBM could allowstratiﬁcation of aggressive management to the patient group
where it would be most beneﬁcial to quality of life. Osteosarcoma
patients with ALT[+] tumors could beneﬁt from a quantitative
blood test for ALT to monitor for success of pre-operative chemo-
therapy in time to alter it if required [31]. If ALT targeted antican-
cer therapies eventuate it will be necessary to know the extent of
ALT activity in normal tissue. There have been suggestions of ALT
activity in activated mouse lymphocytes [86] and mouse embryo-
nal cells [86,105]. Investigation of ALT-like activity in early mouse
embryonic cells also indicate that meiosis-speciﬁc homologous
recombination proteins may be involved [105].
Investigations of ALT in cancer have also had implications for
understanding ALT regulation. ALT does appear to be more com-
mon in sarcomas and astrocytomas than in carcinomas. The prev-
alence of ALT in astrocytomas and sarcomas is 25–60%, whereas in
most carcinomas it appears to range from 5% to 15% (Table 2). This
may reﬂect tighter regulation of telomerase in the tissue type of
origin [27,31], increasing the relative probability that ALT will be
activated when there is selective pressure for activation of a
TMM. Somatic cell hybridization studies have shown that normal
cells contain factors that repress ALT [61], and it is possible that
the level and/or mechanism of ALT repression differs in different
tissue types. The only ALT[+] breast carcinomas identiﬁed so far oc-
curred in the context of either Li-Fraumeni Syndrome (LFS) [5] or
Her-2 gene ampliﬁcation [106]. These data need conﬁrmation in
larger clinical studies, but they could suggest regulation of ALT
by p53 or the Her-2 pathway, respectively. Inactivation of p53
function by viral oncoproteins or mutation is common in ALT cell
lines (Table 3), and p53 appears important for inhibiting HR be-
tween repetitive sequences with short homology [107] as may oc-
cur in ALT [28]. It is also possible that p53 mutation is merely
required for ALT cells to continue to proliferate with their generally
high levels of telomeric DNA damage signals [49,108] and chromo-
somal instability [109–111]. Recently, evidence has emerged sug-
gesting that isocitrate dehydrogenase (IDH) oncogenetic
mutations could be involved in the regulation of ALT. IDH oncoge-
Table 2
Prevalence and prognostic signiﬁcance of ALT in cancer.
Tumor Total cases ALT[+] (%) Survival of ALT[+] References
Relative to ALT[] Median
Osteosarcoma 168 59 NSD [31] 5 years [31] [5,31,121,122]
Gastric carcinoma 42 38 [123]
Soft Tissue Sarcoma 366 30 NSD [31] 4 years [31] [31,102,110,124–127]
Leiomyosarcoma 21 57 [31,110,124,125]
MFH 78 46 Worse [127] NSD [31] 3 years [31] [31,110,124,125,127]
Liposarcoma 187 29 Worse [102] [31,102,110,124–126]
Rhabdomyosarcoma 40 5 [31,110,124,125]
Astrocytoma 117 28 [31,104]
Grades 2 and 3 8 88 [31]
Grade 4 (GBM) 109 24 Better [31,104] 2 years[31] [31,104]
DMP Mesothelioma 38 26 NSD [128] [128]
Adrenocortical carcinoma 87 14 [129]
Ovarian carcinoma 15 13 [5]
Melanoma 9 11 [5]
Neuroblastoma 121 9 Worse [130] 4 years [130] [130]
Breast carcinoma 85 5 [5,106]
Colon carcinoma 22 0 (J.H. and R.R. unpub. results)
Ewings sarcoma 30 0 [111]
Lung carcinoma 7 0a [5]
Papillary thyroid 17 0 [31]
MFH, malignant ﬁbrous histiocytoma; GBM, glioblastoma multiforme; DMP Mesothelioma, diffuse malignant peritoneal mesothelioma; NSD, no signiﬁcant difference.
a Retrospective analysis suggests that telomere lengthening attributed to telomerase in 2/40 Non Small Cell Lung Carcinomas was due to ALT [131].
Table 3
Examples of human ALT cell lines.
Cell Line Cell type Transformation P53 alteration References
GM847 Fibroblast, skin SV40 Viral oncogene [3]
GM0637 (NSV) Fibroblast, skin SV40 Viral oncogene [132]
LM217, KB319 Fibroblast, skin SV40 Viral oncogene [29]
HSF E-2B Fibroblast, foreskin SV40 Viral oncogene [133]
JFCF-6/T.1R and 1J series Fibroblast, jejunal SV40 Viral oncogene [30]
WI38-VA13/2RA Fibroblast, lung SV40 Viral oncogene [3]
SW26-I Fibroblast, lung SV40 Viral oncogene [134]
SV/HF-5/39 Fibroblast, bone marrow SV40 Viral oncogene [135]
MRC5-V2 Fibroblast, lung SV40 Viral oncogene [66]
WHE-7 E7 Cl 1,2,3,4 Fibroblast, embryo HPV E7 Not known [136]
WHE-7 E6/E7 Cl 3 Fibroblast, embryo HPV E6 and E7 Viral oncogene [136]
82-cycA2 Fibroblast, foreskin Cyclin A2 Reduced expression [137]
82-cdk1 Fibroblast, foreskin CDK1 Reduced expression [137]
KMST-6 Fibroblast, embryo Gamma irradiation Mutated [138] [139]
OUMS-24F Fibroblast, embryo Chemical Mutated [138] [140]
SUSM-1 Fibroblast, liver Chemical Mutated [138] [3]
AT1BR44 neo Fibroblast, skin; ATa SV40 Viral oncogene [141]
AT13LA(SV) Fibroblast, skin; AT SV40 Viral oncogene [141]
AT18LA(SV) Fibroblast, skin; AT SV40 Viral oncogene [141]
IIICF/a2, /b4, /b5, /c, .2/A1 Fibroblast, breast; LFSb Spontaneous LOHd [10] [3,10,30]
IIICF-T series Fibroblast, breast; LFS SV40 Viral oncogene [3]
IIICF-E series Fibroblast, breast; LFS HPV E6 +/- E7 Viral oncogene [3]
HMS50-E7 Fibroblast, breast; LFS HPV E7 LOHc [142] [142]
MDAH087 series Fibroblast, skin; LFS Spontaneous LOH [143] [26,143]
LCS-AF.1-2, .1-3, .3-1 Fibroblast, skin; LFS Aﬂatoxin B1 LOH [144] [143,144]
LCS-4X2 Fibroblast, skin; LFS X-Irradiation LOH [145] [143,145]
LFS-05F-24 Fibroblast, skin; LFS Spontaneous LOH [66] [66]
W-V Fibroblast, WSd SV40 Viral oncogene [59]
AG11395 Fibroblast, WS SV40 Viral oncogene [59,60]
MeT-4A Mesothelial SV40 Viral oncogene [3]
H295R Adrenocortical Tumor Not known [146]
Saos-2 Osteosarcoma Tumor Mutated [147] [5]
G-292 Osteosarcoma Tumor Mutated [148] [5]
U-2 OS Osteosarcoma Tumor Wild-typee [149] [5]
ZK-58 Osteosarcoma Tumor Wild-type [109] [109]
SK-LU-1 Adenocarcinoma, lung Tumor Mutated [150] [5]
DOS16 Leiomyosarcoma; LFSb Tumor Not known [66]
BET-3M Epithelial, bronchial SV40 Viral oncogene [3]
HIO107, 117 and 118 Epithelial, ovarian SV40 Viral oncogene [48]
OKF6-D1/Dp53 Keratinocyte, oral Cyclin D1, p53 Dominant-negative [151]
a AT, Ataxia Telangiectasia.
b LFS, Li-Fraumeni syndrome.
c LOH, loss of heterozygosity for wild-type p53.
d WS, Werner syndrome.
e Seven-fold increase in MDM2.
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glioma [112,113] which, like ALT, are associated with better sur-
vival and other characteristics of secondary GBM and are present
in the majority of grades 2 and 3 astrocytomas from which second-
ary GBM originate [31,112]. IDH oncogenetic mutations alter key
metabolite and redox balances in the cell and may activate the
cells’ hypoxia pathway [114,115]. It is not clear how this could
modulate ALT activity, but it would be of interest to conﬁrm the
association of ALT and IDH oncogenetic mutations directly in
GBM and other cancer types.
5. Considerations regarding the ALT mechanism
Data considered here suggest there may be two types of telo-
meric recombination activities that are essential for ALT[+] cells.
Firstly, there are sporadic elongations of individual telomeres
[14,28,29] with the ampliﬁed DNA templated from the same [62]
or a different telomeric allele [6,28]. These elongations are variable
in length and may be large [28,29], suggesting HR-primed replica-
tion from either a long linear template or a rolling template. An-
other explanation of sudden, large increases in length could be
RCA of telomeric DNA extra-chromosomally [66,98] and then inte-
gration into a telomere. Secondly there may be an ALT recombina-
tion activity related to the processing of aberrant replication or
recombination structures on ALT telomeres. Long arrays or deﬁ-
cient heterochromatization of repetitive DNA could cause replica-
tion difﬁculties in ALT telomeres. Depletion of the HR protein,
RAD51D [116], or several HR-associated proteins diminishes the
viability of ALT cells [23–25,54,87,101] without any evidence of
inhibiting ALT telomeric elongation. Both processing of aberrant
structures and ALT elongation might occur in APBs
[23,24,41,47,54]. In mice, defective telomeric heterochromatiza-
tion leads to increased telomeric HR, APBs and telomere elongation
[117–119]. Thus perhaps the unusual instability at ALT telomeres
could facilitate ALT telomere elongation by promoting either HR-
primed replication or the creation of C-circles. Elucidation of the
ALT mechanism and translation of this research to beneﬁt cancer
patients will be facilitated by ﬁnding ALT-speciﬁc proteins or mol-
ecules that can be utilized for diagnosis, or monitoring of therapy,
or targeted by inhibitors for therapeutic purposes.
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